David Boalleti's Colleagues at Matinas BioPharma
David Boalleti's Contact Details
908-484-8805
Matinas BioPharma
David Boalleti's Company Details
Matinas is focused on improving the intracellular delivery of critical therapeutics through its LNC delivery platform and is developing its own portfolio of products and partnering with leading pharma companies to develop new formulations that take full advantage of the LNC platform.Preclinical & clinical data have shown this novel tech can provide solutions to many of the challenges in achieving safe & effective intracellular delivery, for both small & larger, more complex molecules. The combination of a unique MoA and flexibility in the formulation and route of administration, position our LNC tech to potentially become the preferred next-gen intracellular drug delivery vehicle and an improvement over lipid nanoparticles and viral vectors.MAT2203 is an oral, LNC formulation of the highly effective, but highly toxic, antifungal medicine amphotericin B, primarily used as a 1st-line treatment for invasive fungal infections. MAT2203 is in a Ph. 2 open-label, sequential cohort study (EnACT) in HIV-infected patients with cryptococcal meningitis. EnACT has completed the first 2 patient cohorts. Efficacy data from Cohort 2 demonstrated 95% survival and exceeded the prespecified primary endpoint threshold. Cohort 3 enrollment has commenced; enrollment completion expected Q4 2021.MAT2501 is an oral, LNC formulation of the broad-spectrum aminoglycoside antibiotic amikacin, primarily used to treat chronic and acute bacterial infections. MAT2501 would be the 1st oral aminoglycoside. With support from the CF Foundation, initially focused on NTM lung disease, MAT2501 is undergoing preclinical studies and expects to enter Ph. 1 in 2021. LYPDISO™ is a prescription-only omega-3 fatty acid-based composition, comprised primarily of EPA and DPA, intended for the treatment of cardiovascular and metabolic conditions. This next-gen omega-3 therapy has been shown in 2 head-to-head studies to provide effective TG-lowering and significantly higher EPA blood levels than Vascepa®.